Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens

Kuan Hsing Chen, Ja-Liang Lin*, Dan Tzu Lin-Tan, Hsiang Hao Hsu, Ching Wei Hsu, Kuang Hung Hsu, Tzung Hai Yen

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

31 Scopus citations

Abstract

Background: A previous study in type 2 diabetic patients with high-normal body lead burdens showed that EDTA chelation therapy for 3 months slows progressive diabetic nephropathy during a 12-month follow-up. The effect of a longer course of therapy on kidney function decrease over a longer follow-up is not known. Study Design: A 12-month run-in phase, then a randomized single-blind study with a 27-month intervention. Setting & Participants: University medical center; 50 patients (serum creatinine, 1.5-3.9 mg/dL) with high-normal body lead burden (<80-<600 μg) were randomly assigned to the treatment and control groups. Intervention: The treatment group received weekly chelation therapy for 3 months to reduce their body lead burden to <60 μg and then as needed for 24 months to maintain this level. The control group received placebo for 3 months and then weekly for 5 weeks at 6-month intervals for 24 months. Outcomes: The primary end point was change in estimated glomerular filtration rate (eGFR) over time. A secondary end point was a 2-fold increase in baseline serum creatinine level or the requirement for renal replacement therapy. Measurements: Body lead burdens were assessed by EDTA mobilization tests and eGFR was calculated using the equation for Chinese patients with type 2 diabetes. Results: Mean baseline eGFRs in the treatment and control groups were similar. After 3 months of chelation therapy, the change in eGFR in the treatment group (+1.0 ± 4.8 mL/min/1.73 m2) differed significantly from that in the control group (-1.5 ± 4.8 mL/min/1.73 m2; P = 0.04). In the subsequent 24-month intervention, the yearly rate of decrease in eGFR (5.6 ± 5.0 mL/min/1.73 m2 per year) in the treatment group was slower than that (9.2 ± 3.6 mL/min/1.73 m 2 per year; P = 0.04) in the control group. 17 (68%) control-group patients and 9 (36%) treatment-group patients achieved the secondary end point. Limitations: Small sample size, not double blind. Conclusions: A 27-month course of EDTA chelation therapy retards the progression of diabetic nephropathy in type 2 diabetic patients with high-normal body lead burdens.

Original languageEnglish
Pages (from-to)530-538
Number of pages9
JournalAmerican Journal of Kidney Diseases
Volume60
Issue number4
DOIs
StatePublished - 10 2012

Keywords

  • Progressive diabetic nephropathy
  • body lead burden
  • repeated EDTA chelation therapy
  • type 2 diabetes

Fingerprint

Dive into the research topics of 'Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens'. Together they form a unique fingerprint.

Cite this